Genome mapping firm Bionano Q3 rev beats estimates on higher utilization by routine users

Bionano Genomics

13/11/2025 21:18

Overview

Bionano Q3 2025 revenue grows 21% yr/yr, beating analyst expectations

Company's gross margin improves to 46% from (139)% in Q3 2024

Operating expenses reduced by 66% to $11.9 mln

Outlook

Bionano expects Q4 2025 revenue between $7.5 mln and $7.9 mln

Company maintains full-year 2025 revenue guidance of $26 mln to $30 mln

Bionano anticipates over 25 new OGM system installations in 2025

Result Drivers

CONSUMABLES AND SOFTWARE - Increased utilization among routine users drove revenue growth, per CEO Erik Holmlin

EXPANSION IN JAPAN - Growing utilization of optical genome mapping in Japan supports revenue growth

OGM SYSTEM INSTALLATIONS - Installation of new OGM systems contributed to revenue increase

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$7.40 mln
$6.87 mln (3 Analysts)
Q3 Gross Margin
46.00%
Q3 Adjusted Operating Expenses
$9.70 mln
Q3 Operating Expenses
$11.90 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Bionano Genomics Inc is $9.50, about 83.2% above its November 12 closing price of $1.60

Press Release: ID:nGNX7TFQMF

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)